Page 464«..1020..463464465466..470480..»

The Adult Stem Cell Technology Center, LLC Presents Its New Company Initiatives At The 2014 BioPharm America …

By LizaAVILA

Boston, Massachusetts (PRWEB) September 25, 2014

The ASCTCs (website) Director James L. Sherleys first BioPharm America (conference website) experience got off to a remarkable beginning on Day 1 of the conference. After an impromptu decision to participate in the events Perfect Pitch competition, which involved about 40 company contestants, ASCTC tied for second place. As one of a few companies in the stem cell and regenerative medicine space at the conference, this success led to some attendees referring to Sherley as that stem cell guy. Sherley smiled, I take it as a fun compliment. I do think it was the unique presence of ASCTC as one of a few stem cell companies present in a sea of drug development companies that contributed to our success.

However, the ASCTCs pitch to a panel of Pharma investors was in fact more about drugs than stem cells. Sherley pitched the companys partnership venture with AlphaSTAR Corporation (ASC; website) located in Long Beach, California. ASC develops computer simulation analyses to predict the integrity failure of complex composite materials used to build aircraft, racing cars, and other high stress vehicles like the space shuttle. The two companies have integrated their respective expertise to produce a first-of-its-kind computer simulation-based technology for identifying, at the beginning of the drug development pipeline, drug candidates that are toxic to tissue stem cells. Such toxicity causes drugs to fail in expensive preclinical studies and clinical trials, and even after marketing.

At the conference, Sherley commented, I think we are starting to get their [drug companies] attention now. In his pitch of the new AlphaStem tissue stem cell toxicity technology, he emphasized that the ASCTC projects that this technology could save the U.S. Pharma industry about $4 billion of the estimated $40 billion that it spends on failed drug candidates each year. Besides reducing cost and accelerating the development of needed new drugs, the AlphaStem technology would reduce that exposure of patients to particularly harmful drug candidates.

The ASCTC was not the only company at the conference active within the regenerative medicine space. On the first evening of the conference, ASCTC was one of several guest companies and academic institutions in the regenerative medicine space that were invited to a VIP dinner co-hosted by BioPharm Americas producer, EBD Group, and the Alliance for Regenerative Medicine. The guest party dined at the Top of the Hub Restaurant on the top floor of Bostons Prudential Tower.

BioPharm America conferences are designed to arrange many one-to-one meetings among participants of diverse expertise in the international pharmaceutical industry. Over the three-day conference, ASCTC Director Sherley met with Pharma executives, contract research organization directors, Pharma business development consultants, and Pharma investment group partners towards establishing new strategic relationships for the company.

On the final morning of the conference, the ASCTC was one of eleven companies selected to present in the Next Generation Company session. Director Sherley focused his presentation on how the ASCTCs unique expertise in tissue stem cell asymmetric self-renewal gives the company its exclusive position in commercialization of technologies for counting, manufacturing, and monitoring human tissue stem cells. Asymmetric self-renewal is the defining property of tissue stem cells that allows them to maintain the genomic blueprint of human tissues while continuously producing the building block cells of body tissues at the same time. Sherley expressed that asymmetrically self-renewing stem cells in organs and tissues of children and adults will eventually be understood as the fulcrum at the center, between the mature industry of pharmaceutical therapeutics and the emerging industry of cell-based therapeutics. Thats the ASCTC vision.

************************************************************************************************************* The Adult Stem Cell Technology Center, LLC is a Massachusetts life sciences company established in September 2013 (ASCTC; join mailing list). ASCTC Director and founder, James L. Sherley, M.D., Ph.D. is the foremost authority on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the three main technical problems production, quantification, and monitoring that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells. Currently, ASCTC is employing its technological advantages to pursue commercialization of mass-produced therapeutic human liver cells and facile assays that are early warning systems for drug candidates with catastrophic toxicity due to adverse effects against adult tissue stem cells.

More here:
The Adult Stem Cell Technology Center, LLC Presents Its New Company Initiatives At The 2014 BioPharm America ...

To Read More: The Adult Stem Cell Technology Center, LLC Presents Its New Company Initiatives At The 2014 BioPharm America …
categoriaUncategorized commentoComments Off on The Adult Stem Cell Technology Center, LLC Presents Its New Company Initiatives At The 2014 BioPharm America … | dataSeptember 25th, 2014
Read All

Basic Evaluation Before PRP and Stem Cell Therapy in Osteoarthritis Knee – Video

By daniellenierenberg


Basic Evaluation Before PRP and Stem Cell Therapy in Osteoarthritis Knee
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

See the rest here:
Basic Evaluation Before PRP and Stem Cell Therapy in Osteoarthritis Knee - Video

To Read More: Basic Evaluation Before PRP and Stem Cell Therapy in Osteoarthritis Knee – Video
categoriaUncategorized commentoComments Off on Basic Evaluation Before PRP and Stem Cell Therapy in Osteoarthritis Knee – Video | dataSeptember 25th, 2014
Read All

Nishan – Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) – 23-04-2014 – Video

By Sykes24Tracey


Nishan - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) - 23-04-2014
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

Read the original post:
Nishan - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) - 23-04-2014 - Video

To Read More: Nishan – Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) – 23-04-2014 – Video
categoriaUncategorized commentoComments Off on Nishan – Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) – 23-04-2014 – Video | dataSeptember 25th, 2014
Read All

Vivek – Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) – Video

By LizaAVILA


Vivek - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD)
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

See the article here:
Vivek - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) - Video

To Read More: Vivek – Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) – Video
categoriaUncategorized commentoComments Off on Vivek – Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) – Video | dataSeptember 25th, 2014
Read All

Tonsil stem cells could someday help repair liver damage without surgery

By LizaAVILA

PUBLIC RELEASE DATE:

24-Sep-2014

Contact: Michael Bernstein m_bernstein@acs.org 202-872-6042 American Chemical Society @ACSpressroom

The liver provides critical functions, such as ridding the body of toxins. Its failure can be deadly, and there are few options for fixing it. But scientists now report in the journal ACS Applied Materials & Interfaces a way to potentially inject stem cells from tonsils, a body part we don't need, to repair damaged livers all without surgery.

Byeongmoon Jeong and colleagues point out that currently, the only established method for treating liver failure or severe cases of liver disease is complete or partial transplantation. But the need is much greater than the number of available organs. Plus, surgery has inherent risks and a hefty price tag. A promising alternative in development is transplanting liver cells. One such approach involves using adult stem cells to make liver cells. Stem cells from bone marrow could be used, but they have limitations. Recently, scientists identified another source of adult stem cells that could be used for this purpose tonsils. Every year, thousands of surgeries are performed to remove tonsils, and the tissue is discarded. Now it could have a new purpose, but scientists needed a way to grow them on a 3-D scaffold that mimics real liver tissue. Jeong's team set out to do just that.

The researchers encapsulated tonsil-derived stem cells in a heat-sensitive liquid that turns into a gel at body temperature. They added substances called growth factors to encourage the stem cells to become liver cells. Then, they heated the combination up to a normal body temperature. The result was a 3-D, biodegradable gel that contained functioning liver cells. The researchers conclude that the same process has promise with some further tweaking for ideal conditions as an injectable tissue engineering technique to treat liver disease without surgery.

###

The authors acknowledge funding from the National Research Foundation of Korea.

The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 161,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.

See more here:
Tonsil stem cells could someday help repair liver damage without surgery

To Read More: Tonsil stem cells could someday help repair liver damage without surgery
categoriaBone Marrow Stem Cells commentoComments Off on Tonsil stem cells could someday help repair liver damage without surgery | dataSeptember 24th, 2014
Read All

Stemedix Stem Cell Therapy for ALS – Patient Experience: Dr. Robert K., MD – Video

By Dr. Matthew Watson


Stemedix Stem Cell Therapy for ALS - Patient Experience: Dr. Robert K., MD
Stemedix treats Dr. Robert K., MD. for ALS (Amyotrophic Lateral Sclerosis). Dr. Robert speaks about his patient experience with Stemedix after receiving Stemedix adipose stem cell treatment....

By: Stemedix

Read more:
Stemedix Stem Cell Therapy for ALS - Patient Experience: Dr. Robert K., MD - Video

To Read More: Stemedix Stem Cell Therapy for ALS – Patient Experience: Dr. Robert K., MD – Video
categoriaUncategorized commentoComments Off on Stemedix Stem Cell Therapy for ALS – Patient Experience: Dr. Robert K., MD – Video | dataSeptember 24th, 2014
Read All

Autism complex treatment with stem cell therapy – Video

By NEVAGiles23


Autism complex treatment with stem cell therapy
Get free medical consultation http://www.rivertender.com rivertenderkiev@gmail.com +380636800002.

By:

Continue reading here:
Autism complex treatment with stem cell therapy - Video

To Read More: Autism complex treatment with stem cell therapy – Video
categoriaUncategorized commentoComments Off on Autism complex treatment with stem cell therapy – Video | dataSeptember 24th, 2014
Read All

Swastik – Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) – 23-06-2014 – Video

By Dr. Matthew Watson


Swastik - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) - 23-06-2014
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

See the article here:
Swastik - Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) - 23-06-2014 - Video

To Read More: Swastik – Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) – 23-06-2014 – Video
categoriaUncategorized commentoComments Off on Swastik – Stem Cell Therapy in Duchenne Muscular Dystrophy (DMD) – 23-06-2014 – Video | dataSeptember 24th, 2014
Read All

Tse Named Director of Bone Marrow Transplantation Division at University of Louisville

By NEVAGiles23

Contact Information

Available for logged-in reporters only

Newswise LOUISVILLE, Ky. William Tse, M.D., associate professor of medicine and eminent scholar in hematologic malignancies research at the Mary Babb Randolph Cancer Center at West Virginia University, has been named the new director of Bone Marrow Transplantation at the University of Louisville James Graham Brown Cancer Center, a part of KentuckyOne Health. Tse will join UofL Nov. 1.

Tse will hold the Marion F. Beard Endowed Chair in Hematology Research at UofL and become a member of the cancer centers Developmental Biology Program.

Dr. Tse is emerging as one of the thought leaders in bone marrow transplantation, said Donald Miller, M.D., Ph.D., director of the JGBCC. He has trained and worked at several of the leading blood cancer programs in the nation. We look forward to his leading our program at UofL.

Tse has been at West Virginia since 2009, where he also is the co-leader the Osborn Hematologic Malignancies Program. Prior to joining West Virginia, Tse was on the faculty at the University of Colorado Denver, where he was the director of translational research program for bone marrow transplantation and hematologic malignancies. He also previously was with Case Western Reserve University and the Fred Hutchinson Cancer Research Center/University of Washington Medical Center.

Tse is active in national organizations, serving in several capacities with the American Society of Hematology, including section chair for the annual meetings Oncogene Section and bone marrow transplantation outcome section, as well as the American Society of Clinical Oncology as an annual meeting abstract reviewer and the section chair on geriatric oncology. Tse also serves leadership roles on several editorial boards including as the senior editor of the American Journal of Blood Research, stem cell biomarkers section editor for Biomarker Research, senior editor of the American Journal of Stem Cells and the academic editor of PLoS One.

A graduate of the Sun Yat-Sen University School of Medicine in Guangzhou, Guangdong, in China, he did a thoracic surgical oncology residency at Sun Yat-Sen University Cancer Center in Guangzhou before completing postdoctoral research fellowships in medical biophysics, immunology and cancer at the Princess Margaret Hospital/Ontario Cancer Institute and the Hospital for Sick Children in Ontario, Canada. He completed clinical pathology and internal medicine residencies at North Shore-Long Island Jewish Hospital before undertaking a senior medical fellowship in clinical research and medical oncology divisions at the Fred Hutchinson Cancer Research Center at the University of Washington Medical Center.

Follow this link:
Tse Named Director of Bone Marrow Transplantation Division at University of Louisville

To Read More: Tse Named Director of Bone Marrow Transplantation Division at University of Louisville
categoriaBone Marrow Stem Cells commentoComments Off on Tse Named Director of Bone Marrow Transplantation Division at University of Louisville | dataSeptember 23rd, 2014
Read All

Stem cell centre proposed for resort

By LizaAVILA

Xia Jie.

Medical entrepreneur Xia Jie, whose company Health 100 owns the largest chain of health clinics in China, plans to open overseas facilities to cater for wealthy clients.

That could result in an investment of about $20 million in a regenerative treatment centre in the resort, making it a Mecca for health tourism and athlete injury rehabilitation.

''We're now negotiating with the local medical teams,'' Mr Xia said yesterday through an interpreter while on a four-day fact-finding mission to Queenstown.

''Health 100 really wants to find beautiful cities around the world to take Chinese patients to and Queenstown is one of them.

''The vision is to bring the very high-end customers to have special treatment which is not carried out elsewhere in the world,'' he said.

Health 100 would invest with existing firms Queenstown Regenerative Medicine (QRM), run by Marcelle Noble, and the Queenstown Skin Institute.

Both have small premises at Remarkables Park in Frankton.

Queenstown Skin Institute director Dr Hans Raetz said Mr Xia had indicated plans for a much larger centre, with sites in Remarkables Park, Jacks Point or the Five Mile development off Frankton Ladies Mile already earmarked.

''The size depends on Mr Xia, but we've been talking between $10 million and $20 million.

Read more from the original source:
Stem cell centre proposed for resort

To Read More: Stem cell centre proposed for resort
categoriaUncategorized commentoComments Off on Stem cell centre proposed for resort | dataSeptember 23rd, 2014
Read All

Local man shares his story of stem cell donation

By daniellenierenberg

When a child became ill, Jim Pattison was one of many who stepped up as a potential bone marrow donor.

Herald photo by Jodi Schellenberg

Jim Pattison was given two paperweights for his stem cell donation. He decided to become a donor in 1996, but was not a match until after 2010.

In 1996, Pattison was one of many who went on the bone marrow transplant list to help a one and a half year old child who was diagnosed with acute myeloid leukemia. The organizers of the donor drive expected maybe 50 people to show up and were shocked by the close to 400 who attended.

Sadly, the family didnt find a match and the girl died, but Pattison decided to stay on the registry.

They asked if I wanted to stay on and my answer was that if I would do it for Abigail I would do it for anybody, he said.

Throughout the years, Pattison was asked to test for more markers to see if he would be a match for someone else. He did his last test in 2010 and heard back a short time later with the news he was a match.

Pattison was chosen for a peripheral stem cell donation, which is different from a bone marrow transplant because it is less invasive.

I first went to where the stem cells are collected and had a physical, he explained. They sent me back with some drugs that I had to have injected here, that stimulate the stem cells to grow. I had four injections before I went.

They were looking to make sure I had a high enough level of stem cells to make the donation, he added.

More:
Local man shares his story of stem cell donation

To Read More: Local man shares his story of stem cell donation
categoriaBone Marrow Stem Cells commentoComments Off on Local man shares his story of stem cell donation | dataSeptember 23rd, 2014
Read All

Colchester teen becomes one of the UK's youngest stem cell donors

By daniellenierenberg

A teenager who gave stem cells to save the life of a stranger is backing a national campaign to find more donors.

In June, Celyn Evans, 17, became one of the youngest people in the UK to donate stem cells.

The Colchester Royal Grammar School sixth-form student is supporting Anthony Nolans Save a Life at 16 campaign.

The charity wants HMRC to include details about stem cell donation when it writes to teens with their National Insurance numbers ahead of their 16th birthday.

Celyn, of West Mersea, said: You often hear that young people are self absorbed and not interested in helping others, but I think thats wrong.

People just need to be made aware of how they can help. That is why I am supporting this campaign.

Celyn joined the bone marrow donor register last September when his brothers friend developed leukaemia.

He was not able to help the family friend, but in February, Anthony Nolan contacted him to say he was a possible match for another patient in need of a potentially life-saving transplant.

Celyn agreed to donate and, after a series of check-ups, made the donation in London in June.

Like 90 per cent of donors, he gave his stem cells through a simple, outpatient process similar to giving blood.

Read the original:
Colchester teen becomes one of the UK's youngest stem cell donors

To Read More: Colchester teen becomes one of the UK's youngest stem cell donors
categoriaBone Marrow Stem Cells commentoComments Off on Colchester teen becomes one of the UK's youngest stem cell donors | dataSeptember 23rd, 2014
Read All

Colchester: Selfless teen stem cell donor Celyn Evans backs campaign to find more young heroes

By Dr. Matthew Watson

Celyn Evans, 17, from Colchester, has donated stem cells to save the life of a complete stranger. Pictured with the stem cells.

Monday, September 22, 2014 10:49 AM

A selfless teenager from Colchester who donated stem cells to a stranger is backing a campaign to help find more young heroes.

To send a link to this page to a friend, you must be logged in.

In June Celyn Evans, 17, became one of the youngest such donors in the UK.

He was contacted by the Anthony Nolan Trust as a possible match after joining the bone marrow register last September when his brothers friend developed leukaemia.

Now he is supporting Anthony Nolans Save A Life At 16 campaign, calling on HMRC to include details about stem cell donation when it writes to people with their National Insurance number ahead of their 16th birthday.

Celyn said: You often hear that young people are self absorbed and not interested in helping others, but I think thats wrong. People just need to be made aware of how they can help.

Its a very simple process, and I am surprised more people dont do it. But I think its just down to people knowing about it, which is where Anthony Nolans idea comes in.

For more information or to join the register visit the Anthony Nolan Trust website.

Visit link:
Colchester: Selfless teen stem cell donor Celyn Evans backs campaign to find more young heroes

To Read More: Colchester: Selfless teen stem cell donor Celyn Evans backs campaign to find more young heroes
categoriaBone Marrow Stem Cells commentoComments Off on Colchester: Selfless teen stem cell donor Celyn Evans backs campaign to find more young heroes | dataSeptember 23rd, 2014
Read All

Germantown

By Sykes24Tracey

Company plans for the future of stem cell use

by Samantha Schmieder

Staff Writer

Next Healthcare Inc. of Germantown recently launched a partnership with Arizona Cardinals wide reciever Larry Fitzgerald to promote its newest venture, CelBank Pro to other professional athletes.

Next Healthcares CelBank is the collection of cell samples and storage of their blood, skin or stem cells to be used in the future. Stem cells are unspecialized cells that are able to renew themselves through cell division and can be scientifically manipulated to become another type of cell with a more specialized function. They offer hope to provide new ways to fight disease or injuries, according to the National Institutes of Health.

Essentially we are in the business of banking cells for people, Vin Singh, the founder and CEO of Next Healthcare, said.

While CelBank is geared toward anyone interested in using their own cells later in their life, CelBank Pro is geared toward sports players who are very likely to get injured or just worn down during their career.

Skin cells and stem cells are stored at a healthy time at someones life for later use in regenerative medicine, Singh said.

In 2006 and 2007, Singh, who lives in Boyds, heard about a method in Japan that was able to turn adult skin cells into stem cells. Singh decided to build Next Healthcare around these induced pluripotent stem cells, or iPS cells.

For me that was the real spark. I heard about that and thought, Wow, this is an amazing, revolutionary breakthrough, Singh said. Thats where the idea came from, what can we do with that technology. There has to be something that I can do for consumers to give them an advantage.

Continue reading here:
Germantown

To Read More: Germantown
categoriaSkin Stem Cells commentoComments Off on Germantown | dataSeptember 23rd, 2014
Read All

Germantown's Next Healthcare pairs with NFL player

By daniellenierenberg

Company plans for the future of stem cell use

by Samantha Schmieder

Staff Writer

Next Healthcare Inc. of Germantown recently launched a partnership with Arizona Cardinals wide reciever Larry Fitzgerald to promote its newest venture, CelBank Pro to other professional athletes.

Next Healthcares CelBank is the collection of cell samples and storage of their blood, skin or stem cells to be used in the future. Stem cells are unspecialized cells that are able to renew themselves through cell division and can be scientifically manipulated to become another type of cell with a more specialized function. They offer hope to provide new ways to fight disease or injuries, according to the National Institutes of Health.

Essentially we are in the business of banking cells for people, Vin Singh, the founder and CEO of Next Healthcare, said.

While CelBank is geared toward anyone interested in using their own cells later in their life, CelBank Pro is geared toward sports players who are very likely to get injured or just worn down during their career.

Skin cells and stem cells are stored at a healthy time at someones life for later use in regenerative medicine, Singh said.

In 2006 and 2007, Singh, who lives in Boyds, heard about a method in Japan that was able to turn adult skin cells into stem cells. Singh decided to build Next Healthcare around these induced pluripotent stem cells, or iPS cells.

For me that was the real spark. I heard about that and thought, Wow, this is an amazing, revolutionary breakthrough, Singh said. Thats where the idea came from, what can we do with that technology. There has to be something that I can do for consumers to give them an advantage.

See the rest here:
Germantown's Next Healthcare pairs with NFL player

To Read More: Germantown's Next Healthcare pairs with NFL player
categoriaSkin Stem Cells commentoComments Off on Germantown's Next Healthcare pairs with NFL player | dataSeptember 23rd, 2014
Read All

BioKidz: the Children of the Stem Cell Revolution to go Global

By NEVAGiles23

(PRWEB UK) 22 September 2014

BioKidz is a simple concept which aims to engage children in the importance of stem cell medicine. Aimed at an audience of 4-9 year olds, the company now aims to use it in the 21 countries in which it operates.

BioEden has been invited to speak with parents and teachers later this month, as the BioKidz site aims to be a good source of scientific information for primary school teachers.

The BioEden proposition is very simple one: harvest the stem cells from a naturally shed baby tooth, store the viable cells for future therapeutic use, and guarantee that the cells will be available when needed.

As stem cell medicine is now becoming commonplace, it is important that there is a stem cell match when needed. The easiest way to do this is by harvesting and storing one's own cells, and there is no easier way than from naturally shed teeth.

The company admits that they could be putting the ordinary tooth fairy out of business, but they hasten to add that BioKidz have their own hero in the form of a Super Tooth Fairy who works within their own stem cell laboratories.

Children can meet BioEden the Super Tooth Fairy by visiting http://www.bioeden.com.

Continue reading here:
BioKidz: the Children of the Stem Cell Revolution to go Global

To Read More: BioKidz: the Children of the Stem Cell Revolution to go Global
categoriaUncategorized commentoComments Off on BioKidz: the Children of the Stem Cell Revolution to go Global | dataSeptember 23rd, 2014
Read All

Bone paste could provide treatment for ostoeporosis

By raymumme

About three million Briton currently suffer osteoporosis which is affected by a number factors such as genes, a lack of exercise and poor diet and results in about 60,000 hip, 50,000 wrist and 120,000 spinal fractures every year, according to the National Osteoporosis Society, costing about 1.7 billion in health and social care.

Dr Ifty Ahmed, a researcher at Nottingham University, said his team wanted to provide a preventative treatment, strengthening the bones of those at risk before they suffered a fracture.

Speaking at the Regener8 conference on regenerative medicine, in Leeds last week, he said: Our aim would be to use screening to spot people who are at risk, then strengthen their bones before they get fractures.

It means that rather than waiting until people have a fall and break something, we would try to stop that ever happening, along with the consequences, loss of independence, surgery and secondary illnesses.

Previous attempts have been made to find ways of strengthening thinning bones but the difficulties of protecting the fragile stem cells has meant no such treatments have yet been developed.

Dr Ahmeds team hope to overcome this problem by puncturing the tiny hollow spheres of calcium phosphate allowing the stem cells to migrate inside them where they are protected.

The experimental treatment has not yet been trialled on humans.

It would involve extracting stem cells from a patients bone marrow and mixing them with the microspheres before injecting the paste into the vulnerable bones.

Dr Ahmed said: "If it works, this kind of treatment could be done in a day.

Until now the team have been funded by the Engineering and Physical Sciences Research Council but they are now looking for a commercial partner.

Read the rest here:
Bone paste could provide treatment for ostoeporosis

To Read More: Bone paste could provide treatment for ostoeporosis
categoriaBone Marrow Stem Cells commentoComments Off on Bone paste could provide treatment for ostoeporosis | dataSeptember 21st, 2014
Read All

First-in-man procedure utilizes a new method of stem cell delivery

By JoanneRUSSELL25

Frankfurt, Germany (PRWEB) September 19, 2014

The Translational Research Institute TRI Medical announced today that its new ND Infusion Catheter is being used in a first-in-man procedure at the University of Frankfurt.

The study commenced on September 4th, 2014 at the University of Frankfurt, Department of Cardiology. The use of the new catheter demonstrated a number of advancements in the delivery of regenerative therapeutics, commonly known as stem cells. We are at the forefront of revolutionizing stem cell delivery to the heart, TRI Medicals Nabil Dib, MD, Msc, offered. The ND Infusion Catheter provides safety and potential efficacy. The catheter also reduces the procedure time to approximately 15 minutes; enabling patients to walk and resume activities in about 2 hours, Dr. Dib continued.

The renowned German Cardiology Center at the University of Frankfurt has extensive experience with the development of cardiac cell-based regenerative therapeutics. Prof. Dr. Andreas M. Zeiher, Chairman of the Department of Cardiology at the University of Frankfurt stated The catheter provides the unique potential to precisely regulate coronary blood flow, while administering cells directly into the heart thus improving safety and potentially efficacy. The innovative design of the catheter's balloon accommodates different vessel sizes, avoiding the need to use multiple catheters, reducing potential risks associated with exchanging the balloon catheter when treating different coronary arteries in an individual patient.

Prior to the first-in-man procedure, extensive cell compatibility testing of bone marrow derived cells with the ND Infusion Catheter revealed that the catheter preserved cell viability and functionality, Stefanie Dimmeler, PhD and Director of the Institute of Cardiovascular Regeneration, Centre of Molecular Medicine stated. The testing proved that the cells are compatible with the ND Infusion Catheter. We see this as potential improvements in safety and clinical outcomes related to cell function and efficacy in patients, Dr. Dimmeler offered.

Safety was top-of-mind when we initiated the first-in-man procedure in Frankfurt. We are elated to report that the procedures outcomes were successful, Dr. Dib stated. Earlier studies revealed that the ND Infusion Catheter reduces cellular clumping, preserves cell viability, improves dispersion and reduces radial forces on the vessel walls during balloon inflation; which collectively might improve patient safety and clinical outcomes.

TRI Medicals Ron Anson, Vice President of Business Development shared The catheters unique design features provide physicians with a valuable new tool in the delivery of specified fluids such as stem cells. We expect to see significant growth in the stem cell research marketplace for the new, state-of-the-art ND Infusion Catheter.

ABOUT TRI Medical TRI Medical is a privately held, medical device development company. TRI Medical is dedicated to providing a pathway to regulatory approval that is efficient, predictable and cost effective.

#####

Media inquiries regarding TRI Medical, its capabilities and for additional information regarding the ND Infusion Catheter contact: DeAnn Dana Phone: 480.309.2884 Email: DDana(at)TRImedical.com TRI Medical website: http://www.trimedical.com

Go here to read the rest:
First-in-man procedure utilizes a new method of stem cell delivery

To Read More: First-in-man procedure utilizes a new method of stem cell delivery
categoriaCardiac Stem Cells commentoComments Off on First-in-man procedure utilizes a new method of stem cell delivery | dataSeptember 20th, 2014
Read All

Bone Marrow Recipient Meets Donor Who Saved His Life

By JoanneRUSSELL25

Two men who changed each others lives forever by being on the giving and receiving ends of a bone marrow transplant met for the first time today and had their first chance to say, Thank you, face-to-face.

Thank you so much, Joe Yannantuono, 33, said to his bone marrow donor, Justin Jenkins, 35, as he embraced him in a hug in a live, emotional meeting on Good Morning America.

Yannantuono, not very long ago, was waging a two-year long battle for his life against stage 4 lymphoma.

WATCH: Robin Roberts Celebrates 1-Year Anniversary of Bone Marrow Transplant

Toddler Meets Life-Saving Bone Marrow Donor

As his wife, Christine Buono, and his 4-year-old son, JJ Yannantuono, stood by his side, the family, from Staten Island, N.Y., got the unbelievable news that a man in Texas, a stranger, was a rare 10 for 10 genetic bone marrow match.

That stranger in Texas, Jenkins, of Dallas, had registered to be a bone marrow donor by chance 15 years ago when he was 21-years-old and donated blood because they were offering free snacks.

Soon after Jenkins was found to be a match, his stem cells were transported by airplane to New York and transplanted into Yannatuonos body in December 2012 at Memorial Sloan Kettering Cancer Center.

For more than one year after the successful transplant, Yannantuono had no idea whose cells he was now carrying in his body.

As Yannantuono was rebuilding his life, Jenkins life was thrown a tragic curveball. His mother, who raised him on her own and had been a big part of his donation journey, was killed in a car crash.

Read the rest here:
Bone Marrow Recipient Meets Donor Who Saved His Life

To Read More: Bone Marrow Recipient Meets Donor Who Saved His Life
categoriaBone Marrow Stem Cells commentoComments Off on Bone Marrow Recipient Meets Donor Who Saved His Life | dataSeptember 20th, 2014
Read All

New molecule allows for up to 10-fold increase in stem cell transplants

By LizaAVILA

Investigators from the Institute for Research in Immunology and Cancer (IRIC) at the Universit de Montral have just published, in the journal Science, the announcement of the discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood. Umbilical cord stem cells are used for transplants aimed at curing a number of blood-related diseases, including leukemia, myeloma and lymphoma. For many patients this therapy comprises a treatment of last resort.

Directed by Dr. Guy Sauvageau, principal investigator at IRIC and hematologist at the Maisonneuve-Rosemont Hospital, the research has the potential to multiply by 10 the number of cord blood units available for a transplant in humans. In addition, it will considerably reduce the complications associated with stem cell transplantation. And it will be particularly useful for non-Caucasian patients for whom compatible donors are difficult to identify.

A clinical study using this molecule, named UM171 in honor of the Universit de Montral, and a new type of bioreactor developed for stem culture in collaboration with the University of Toronto will be initiated in December 2014 at the Maisonneuve-Rosemont Hospital.

According to Dr. Guy Sauvageau, "This new molecule, combined with the new bioreactor technology, will allow thousands of patients around the world access to a safer stem cell transplant. Considering that many patients currently cannot benefit from a stem cell transplant for lack of matching donors, this discovery looks to be highly promising for the treatment of various types of cancer."

The Centre of Excellence for Cellular Therapy at the Maisonneuve-Rosemont Hospital will serve as production unit for these stem cells, and grafts will then be distributed to patients in Montreal, Quebec City and Vancouver for this first Canadian clinical study. Tangible results should be available one year later, that is, in December 2015. The significance of this new discovery is such that over time, conclusive clinical results could revolutionize the treatment of leukemia and other blood-related illnesses.

"These extraordinary advances result from the efforts of a remarkable team that includes extremely gifted students and postdoctoral investigators working in the IRIC laboratories," adds Dr. Guy Sauvageau. "Among them, the first authors of this publication: Iman Fars, doctoral student, and Jalila Chagraoui, research officer, along with the professionals in IRIC's medical chemistry core facility under the direction of Anne Marinier, who optimized the therapeutic properties of this new molecule."

Context

Umbilical cord blood from newborn children is an excellent source of hematopoietic stem cells for stem cell transplants, since their immune system is still immature and the stem cells have a lower probability of inducing an adverse immune reaction in the recipient.

Furthermore, it is not necessary for the immunological compatibility between donor and recipient to be perfect, unlike in a bone marrow transplant. However, in most cases the number of stem cells obtained from an umbilical cord is much too low for treating an adult, and its use is confined above all to the treatment of children. With the new molecule UM171 it will be possible to multiply stem cells in culture and to produce enough of them to treat adults, especially those who are not Caucasian, and who because of the lack of donors have limited access to transplants.

Collaborators from the Maisonneuve-Rosemont Hospital, the British Columbia Cancer Agency, the Ontario Cancer Institute and the Fred Hutchison Cancer Research Center also played an important role in evaluating the biological properties of this new molecule, and those from the University of Toronto in developing the bioreactor.

Read more:
New molecule allows for up to 10-fold increase in stem cell transplants

To Read More: New molecule allows for up to 10-fold increase in stem cell transplants
categoriaBone Marrow Stem Cells commentoComments Off on New molecule allows for up to 10-fold increase in stem cell transplants | dataSeptember 20th, 2014
Read All

Page 464«..1020..463464465466..470480..»


Copyright :: 2024